Rethinking Oncology Trial Strategy: New Approaches for an Evolving Landscape
Webinar Date/Time: Thursday, September 7th, 2023 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST
This webinar will address global oncology trends and how they impact sponsors preparing for early phase oncology trials.
Register Free: https://www.appliedclinicaltrialsonline.com/act_w/global-oncology
Event Overview:
Global oncology R&D continues to expand, bringing exciting new treatment options to patients. Seventy percent of the R&D pipeline is driven by the innovation of biotech companies. This creates immense pressure to deliver novel treatments and secure investor funding in a highly complex environment.
Join this webinar to hear from experts with the IQVIA Institute and IQVIA Biotech about global oncology trends impacting sponsors and how to optimize clinical trial strategy.
Three key take-aways
- Evaluate findings from the 2023 Global Oncology Trends report significant to biotech sponsors
- Explore nuances of early phase oncology trial design and strategy
- Understand considerations for platform design trials to help increase accessibility to new treatment options
- Review progress made to improve representation of race and ethnicity in clinical trial subjects; learn how to build diversity planning in clinical trial protocols
Speakers:
Murray Aitken
Executive Director
IQVIA Institute for Human Data Science
As head of the IQVIA Institute for Human Data Science, Murray Aitken provides policy setters and decision-makers in the global health sector with evidence, analysis, and insights that contribute to the advancement of Human Data Science to improve human health outcomes.
Murray is tasked with creating and managing a research agenda that leaders in global governments, payers, providers, academia, and the life sciences industry use to accelerate the understanding of global trends in disease patterns, data science, and technology. This research is used to foster innovation critical to evidence-based decision-making and the advancement of human health.
He holds an MBA, with distinction, from Harvard University and a Master of Commerce from the University of Auckland in New Zealand.
Gerhard Du Toit
Global Oncology Head
IQVIA Biotech
As Global Head of Oncology, Gerhard Du Toit oversees all aspects of clinical project management to optimize strategic plans and enhance delivery for early and late phase oncology clinical trials. He is committed to delivering compliant, expeditious, ethical solutions that respect patient safety, meet GCP requirements, and add value to the needs of oncology customers. Working for several global clinical research organizations in his career, Gerhard is a seasoned healthcare executive with more than 25 years of experience in project, clinical and data management, business development and statistics.
Register Free: https://www.appliedclinicaltrialsonline.com/act_w/global-oncology
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
Tirzepatide Reduces Heart Failure Risk, Improves Physical Function in HFpEF Patients
November 18th 2024The Phase III SUMMIT trial showed that tirzepatide significantly reduces the risk of worsening heart failure events or death from cardiovascular causes, enhances physical function, and leads to weight loss and reduced inflammation in patients with heart failure with preserved ejection fraction.
Twice-Yearly Lenacapavir Injections Significantly Reduce HIV Risk, PURPOSE 2 Trial Shows
November 13th 2024Full Phase III PURPOSE 2 trial results suggest that twice-yearly lenacapavir could revolutionize HIV prevention by offering a convenient and effective long-acting option for individuals at risk of infection.
